stand and de-liver, page-8

Epitanman, it is not the company I have problems with, it is/was the insane ramping I object too. This is just a message to others to read inbetween the lines and DYOR. All fi the serial CSL, $20 per share bunnies have gone now at least I'm giving some of you something to think about rather than endeavouring to highlight when the next announcement could be.

Their is value attached to the IP of Ropren but little evidence of any marketing/distribution plan. The prenol process is of note - they need an enforceable JV, not an MOU, but along with many, their corp plan is falling by the wayside due to macro factors beyond anyone's control.

I am sure given my DD, the pharma "network" is coming to help with the drive in distribution. How they will be paid is anyone's guess.